These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 19286867)

  • 1. New onset of inflammatory polyarthritis in a patient taking adalimumab.
    Lee M; Petroniene R; Thorne C
    J Rheumatol; 2009 Mar; 36(3):660. PubMed ID: 19286867
    [No Abstract]   [Full Text] [Related]  

  • 2. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract]   [Full Text] [Related]  

  • 3. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD; Richards R
    Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
    Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J
    Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal invasive pulmonary aspergillosis associated with adalimumab therapy.
    Manz M; Beglinger C; Vavricka SR
    Gut; 2009 Jan; 58(1):149. PubMed ID: 19091839
    [No Abstract]   [Full Text] [Related]  

  • 6. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 7. Summaries for patients. Treatment of Crohn disease with anti-tumor necrosis factor agent.
    Ann Intern Med; 2007 Jun; 146(12):I20. PubMed ID: 17470825
    [No Abstract]   [Full Text] [Related]  

  • 8. Basophil activation test in a case of systemic hypersensitivity reaction to infliximab with good tolerance to another anti-TNF-alpha agent (adalimumab).
    Manso L; Polo B; Fernández-Nieto M; Sastre LB; del Pozo V; Sastre J
    J Investig Allergol Clin Immunol; 2010; 20(6):537-8. PubMed ID: 21243942
    [No Abstract]   [Full Text] [Related]  

  • 9. [Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease].
    Avila Alvarez A; García-Alonso L; Solar Boga A; García-Silva J
    An Pediatr (Barc); 2009 Mar; 70(3):278-81. PubMed ID: 19409245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease.
    Jordan N; Waghmare A; Abi-Ghanem AS; Moon A; Salvatore CM
    J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):294-6. PubMed ID: 21694635
    [No Abstract]   [Full Text] [Related]  

  • 11. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
    Baker DE
    Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another?
    Kocharla L; Mongey AB
    Lupus; 2009 Feb; 18(2):169-71. PubMed ID: 19151120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
    Barthel HR; Gille T; Halbsguth A; Kramer M
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma.
    Liozon E; Ouattara B; Loustaud-Ratti V; Vidal E
    Scand J Rheumatol; 2007; 36(6):484-6. PubMed ID: 18092275
    [No Abstract]   [Full Text] [Related]  

  • 18. [Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease].
    Michetti P
    Rev Med Suisse; 2008 Jan; 4(141):187-8. PubMed ID: 18335883
    [No Abstract]   [Full Text] [Related]  

  • 19. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.
    Kooloos WM; de Jong DJ; Huizinga TW; Guchelaar HJ
    Drug Discov Today; 2007 Feb; 12(3-4):125-31. PubMed ID: 17275732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.